/ZBIO
ZBIO Stock - Zenas BioPharma, Inc.
Healthcare|BiotechnologyNASDAQ
$36.15+3.08%
+$1.08 (+3.08%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).90
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+19.9%upside
Target: $43.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ZBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.79 – $36.51
TARGET (TP)$43.33
STOP LOSS$33.26
RISK/REWARD1:2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.57
52W High$41.50
52W Low$5.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $5.00M | $50.00M | N/A |
| Gross Profit | $-134,139,000 | $50.00M | $-61,689,000 |
| Gross Margin | -2682.8% | 100.0% | N/A |
| Operating Income | $-163,888,000 | $-37,147,000 | $-76,199,000 |
| Net Income | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Margin | -3139.8% | -74.2% | N/A |
| EPS | $-3.76 | $-0.97 | $-3.11 |
Company Overview
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$33
Average Target
↓ 8.4% Downside
Now
$19
Low
$33
Average
$45
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 20th 2025 | Wedbush | Initiation | Outperform | $35 |
| February 4th 2025 | Wolfe Research | Initiation | Outperform | $19 |
| December 16th 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| November 5th 2024 | Rodman & Renshaw | Initiation | Buy | $34 |
| October 8th 2024 | Guggenheim | Initiation | Buy | $45 |
| October 8th 2024 | Morgan Stanley | Initiation | Overweight | $40 |
| October 8th 2024 | Jefferies | Initiation | Buy | $35 |
| October 8th 2024 | Citigroup | Initiation | Buy | $27 |
Earnings History & Surprises
ZBIOBeat Rate
40%
Last 5 quarters
Avg Surprise
-64.5%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$-1.22
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q4 24
+46.2%
$-5.02vs$-9.33
Q1 25
-333.7%
$-3.99vs$-0.92
Q2 25
+27.9%
$-0.80vs$-1.11
Q3 25
-22.5%
$-1.25vs$-1.02
Q4 25
-40.2%
$-1.22vs$-0.87
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 11, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.87 | $-1.22 | -40.2% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-1.02 | $-1.25 | -22.5% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-1.11 | $-0.80 | +27.9% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.92 | $-3.99 | -333.7% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-9.33 | $-5.02 | +46.2% | ✓ BEAT |
Q2 2024 | Jun 30, 2024 | — | $-0.99 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-0.73 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.64 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.85 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.76 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.50 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.50 | — | — |
Latest News
Zenas BioPharma's partner, InnoCare Pharma announced the achievement of the primary endpoint in Phase 2b study of orelabrutinib for Systemic Lupus Erythematosus.
📈 PositiveBenzinga•Dec 15, 2025, 12:18 PM•Also:
Evercore ISI Group Initiates Coverage On Zenas BioPharma with Outperform Rating, Announces Price Target of $55
📈 PositiveBenzinga•Nov 26, 2025, 01:14 PM
Morgan Stanley Maintains Overweight on Zenas BioPharma, Raises Price Target to $37
📈 PositiveBenzinga•Nov 13, 2025, 01:11 PM
Zenas BioPharma shares are trading higher. The company reported Q3 financial results.
📈 PositiveBenzinga•Nov 12, 2025, 02:00 PM
Zenas BioPharma Q3 EPS $(1.22) Misses $(0.98) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:17 PM
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $46
📈 PositiveBenzinga•Oct 28, 2025, 04:39 PM•Also:
Morgan Stanley Maintains Overweight on Zenas BioPharma, Raises Price Target to $34
📈 PositiveBenzinga•Oct 28, 2025, 03:31 PM
HC Wainwright & Co. Maintains Buy on Zenas BioPharma, Raises Price Target to $44
📈 PositiveBenzinga•Oct 28, 2025, 11:46 AM
Zenas BioPharma shares are trading higher after the company announced its drug Obexelimab met the primary endpoint in the Phase 2 MoonStone trial.
📈 PositiveBenzinga•Oct 27, 2025, 07:00 PM
Zenas BioPharma Announces Obexelimab Met Primary Endpoint In Phase 2 MoonStone Trial
📈 PositiveBenzinga•Oct 27, 2025, 11:10 AM
Zenas Biopharma Files For Shelf Of Up To 6.3M Shares Of Common Stock By Selling Stockholders
➖ NeutralBenzinga•Oct 21, 2025, 08:53 PM•Also:
Wedbush Maintains Outperform on Zenas BioPharma, Raises Price Target to $40
📈 PositiveBenzinga•Oct 9, 2025, 01:07 PM
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target
📈 PositiveBenzinga•Oct 9, 2025, 10:16 AM
Zenas Biopharma Files For At-The-Market Offering Prospectus Covering Offer Of Up To $200M Common Stock That May Be Issued Under Sales Agreement
➖ NeutralBenzinga•Oct 8, 2025, 08:37 PM
ZBIO stock has given up its prior gain. Zenas BioPharma shares were trading higher after the company announced it secured global rights to InnoCare's orelabrutinib.
📉 NegativeBenzinga•Oct 8, 2025, 02:07 PM
Zenas BioPharma shares are trading higher after the company announced it secured global rights to InnoCare's orelabrutinib.
📈 PositiveBenzinga•Oct 8, 2025, 01:06 PM
Zenas climbs on licensing deal with InnoCare
📈 PositiveSeeking Alpha•Oct 8, 2025, 01:03 PM
Zenas BioPharma Secures Global Rights To InnoCare's Orelabrutinib, Aiming To Advance Multiple Sclerosis Treatments Beyond Oncology
📈 PositiveBenzinga•Oct 8, 2025, 09:05 AM
Royalty Pharma To Provide Up To $300M In Funding To Zenas BioPharma In Exchange For Royalty On Sales Of Obexelimab
📈 PositiveBenzinga•Sep 2, 2025, 11:10 AM•Also:
Frequently Asked Questions about ZBIO
What is ZBIO's current stock price?
Zenas BioPharma, Inc. (ZBIO) is currently trading at $36.15 per share. The stock has moved +3.08% today.
What is the analyst price target for ZBIO?
The average analyst price target for ZBIO is $43.33, based on 1 analyst.
What sector is Zenas BioPharma, Inc. in?
Zenas BioPharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ZBIO's market cap?
Zenas BioPharma, Inc. has a market capitalization of $1.51 billion, making it a small-cap company.
Does ZBIO pay dividends?
No, Zenas BioPharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
NVAX
Novavax, Inc.
$6.66
Mkt Cap: $1.1B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
Explore stocks similar to ZBIO for comparison